Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on FluoGuide's announcement that the first patient has been enrolled in FG001-CT-006, the company's US Phase II trial of FG001 in newly diagnosed high-grade glioma.</li><li>The trial is designed to gather sufficient clinical data to support future registration of FG001.</li><li>We view the enrollment as an important execution milestone that marks the company's transition from regulatory planning to clinical delivery in its lead indication.</li></ul>

Redeye comments on FluoGuide's announcement that the first patient has been enrolled in FG001-CT-006, the company's US Phase II trial of FG001 in newly diagnosed high-grade glioma.The trial is designed to gather sufficient clinical data to support future registration of FG001.We view the enrollment as an important execution milestone that marks the company's transition from regulatory planning to clinical delivery in its lead indication.

FluoGuide: First patient enrolled in US Phase II registration-supporting trial

Fluoguide

FluoGuide: First patient enrolled in US Phase II registration-supporting trial